Erlotinib in non-small-cell lung cancer

被引：13

作者：

Gridelli, Cesare ^{[1
]}

Rossi, Antonio ^{[1
]}

Malone, Paolo ^{[1
]}

Colantuoni, Giuseppe ^{[1
]}

Del Gaizo, Filomena ^{[1
]}

Ferrara, Carmine ^{[1
]}

Nicolella, Dario ^{[1
]}

Guerriero, Ciro ^{[1
]}

机构：

[1] SG Moscati Hosp, Div Med Oncol, I-83100 Avellino, Italy

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2007年 / 8卷 / 15期

关键词：

EGFR; erlotinib; NSCLC; small molecule;

D O I：

10.1517/14656566.8.15.2579

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Epidermal growth factor receptor (EGFR) plays an essential role in normal cell growth and differentiation, and is involved in tumour proliferation and survival. EGFR overexpression is a common feature in solid malignancies, including non-small-cell lung cancer (NSCLC), and is associated with poor clinical prognosis. Erlotinib is a small-molecule inhibitor of EGFR tyrosine kinase, showing a significant improvement in median survival, quality of life and related symptoms in an unselected population of advanced NSCLC patients in the second- or third-line setting. Erlotinib is well tolerated (with common toxicities including rash and diarrhoea) when administered at a standard oral daily dose of 150 mg. Further investigations are ongoing to contribute to our understanding of the role of erlotinilb in NSCLC treatment.

引用

页码：2579 / 2592

页数：14

共 50 条

[1] Erlotinib or Gefitinib for Non-Small-Cell Lung Cancer
Yusuf, Syed W.
Kim, Peter
Durand, Jean-Bernard
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (24): : 2367 - 2367
[2] Erlotinib in the treatment of non-small-cell lung cancer
Kyte, J.
Wilson, P. C.
Dangoor, A.
[J]. LUNG CANCER, 2012, 75 : S6 - S7
[3] Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib
Cataldo, Vince D.
Gibbons, Don L.
Perez-Soler, Roman
Quintas-Cardama, Alfonso
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (10): : 947 - 955
[4] Erlotinib As Maintenance Monotherapy in Non-Small-Cell Lung Cancer
Muir, Victoria J.
Dhillon, Sohita
[J]. BIODRUGS, 2011, 25 (03) : 139 - 146
[5] Erlotinib or Gefitinib for Non-Small-Cell Lung Cancer REPLY
Cataldo, Vince D.
Gibbons, Don L.
Quintas-Cardama, Alfonso
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (24): : 2368 - 2368
[6] Erlotinib in previously treated non-small-cell lung cancer
Shepherd, FA
Pereira, JR
Ciuleanu, T
Tan, EH
Hirsh, V
Thongprasert, S
Campos, D
Maoleekoonpiroj, S
Smylie, M
Martins, R
van Kooten, M
Dediu, M
Findlay, B
Tu, DS
Johnston, D
Bezjak, A
Clark, G
Santabárbara, P
Seymour, L
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02): : 123 - 132
[7] Clinical experience with erlotinib in non-small-cell lung cancer
Felip, Enriqueta
Rosell, Rafael
[J]. DRUGS OF TODAY, 2006, 42 (03) : 147 - 156
[8] Second-line erlotinib for non-small-cell lung cancer
Lorusso, Vito
Cinieri, Saverio
[J]. LANCET ONCOLOGY, 2012, 13 (04): : E141 - E142
[9] Clinical and economic review of erlotinib in non-small-cell lung cancer
Yeung, Kai
Carlson, Josh J.
[J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (04) : 411 - 423
[10] NICE guidance on erlotinib for the maintenance treatment of non-small-cell lung cancer
Rinaldi, Fiona
George, Elisabeth
Clark, Peter
[J]. LANCET ONCOLOGY, 2011, 12 (08): : 728 - 730

← 1 2 3 4 5 →